2:18 PM
 | 
Jul 11, 2018
 |  BC Extra  |  Preclinical News

Turning cancer cells against their own kind

To overcome hurdles facing cancer cell-based therapies such as self-toxicity and long-term persistence, researchers from Brigham and Women's Hospital and colleagues developed a two-part therapy by pairing tumor cells delivering a receptor-targeted anticancer agent with a suicide system.

Harnessing cancer cells as therapies is advantageous compared with stem cell-based therapies because the cancer cells have enhanced homing toward the primary tumor site and...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >